<DOC>
	<DOCNO>NCT00792753</DOCNO>
	<brief_summary>Randomized Study To evaluate safety effectiveness Elixir Medical DESyne Novolimus-Eluting Coronary Stent System Durable Polymer assessment clinical , angiographic IVUS endpoint compare concurrently enrol Medtronic Zotarolimus-Eluting Coronary Stent System randomize , single blind study 200 male female patient . In Continued Access Registry 100 patient receive DESyne Stent clinical-only endpoint evaluate . To evaluate safety effectiveness Elixir Novolimus-Eluting Coronary Stent System bioabsorbable polymer compare Medtronic Endeavor Zotarolimus-Eluting Coronary Stent System control clinical angiographic endpoint .</brief_summary>
	<brief_title>Elixir Medical Clinical Evaluation Novolimus-Eluting Coronary Stent System : A Randomized Study `` EXCELLA II STUDY ''</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>The patient plan intervention single lesion one two separate major epicardial territory . Each lesion/vessel must meet following criterion : De novo The target lesion reference site must visually estimate &gt; 2.5 mm &lt; 3.5 mm diameter . The target vessel must major coronary artery major branch visually estimate stenosis &gt; 50 % &lt; 100 % . The visually estimate target lesion must able covered single , 14 , 18 28mm stent Elixir Stent single 14 , 18 , 24 30mm Endeavor Stent . Note 8mm Endeavor Stent use study . Maximum lesion length 24 mm . &gt; TIMI 1 coronary flow . The patient know hypersensitivity contraindication aspirin , heparin , ticlopidine , clopidogrel , mTOR inhibitor class drug , cobalt chromium alloy , methacrylate polylactide polymer , sensitivity contrast adequately premedicated . There untreated significant lesion &gt; 40 % diameter stenosis remain proximal distal target site plan intervention . Total occlusion TIMI 0 coronary flow target vessel . Restenosis lesion The proximal target vessel target lesion severely calcify visual assessment . Aortoostial location , unprotected leave main lesion location , lesion within 5 mm origin LAD LCX . Lesion involvement significant side branch ( branch diameter &gt; 2 mm ) would cover stenting . The patient suffer myocardial infarction total creatine kinase ( CK ) &gt; 2 time normal within past 72 hour ( exactly three day ) . The patient history bleed diathesis coagulopathy refuse blood transfusion . The patient suffer stroke , transient ischemic neurological attack ( TIA ) significant gastrointestinal ( GI ) bleed within past six month . The patient renal insufficiency determine creatinine &gt; 2.0mg/dl . The target lesion , target vessel proximal target lesion , contain thrombus . Documented leave ventricular ejection fraction &lt; 25 % . The patient recipient heart transplant . The patient extensive peripheral vascular disease precludes safe 6 French sheath insertion extreme anticoagulation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Coronary Artery Disease</keyword>
</DOC>